|
Hold the line, please http://grenstart.com/lau-medical-center-rizk-hospital-beirut-lebanon-981f.pdf#margarita lau medical center-rizk hospital The primary endpoint of improved overall survival was met in the RAINBOW trial. In the REGARD trial, single-agent ramucirumab improved overall survival and progression-free survival in patients with advanced gastric cancer who have had disease progression after initial chemotherapy. The primary endpoint in the ROSE trial was not met because progression-free survival with the use of ramucirumab in women with locally recurrent or metastatic breast cancer was not statistically significant. The interim analysis for overall survival in this trial showed no benefit for ramucirumab.
|